Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: health insurance

Cancer cells

Cancer & RA Drugs: Are Some Drugs Riskier than Others?

Samantha C. Shapiro, MD  |  February 4, 2025

Sendaydiego et al. asked: Do some DMARDs pose a greater cancer risk than others for patients with RA? Here are insights from the study and its clinical implications.

Filed under:ConditionsDrug UpdatesRheumatoid Arthritis

Multiple ACR-Supported Policies Advance at Interim AMA House of Delegates Meeting

From the College  |  November 25, 2024

At a busy and highly successful interim meeting of the AMA House of Delegates, an ACR-cosponsored resolution that calls for exceptions to therapy caps was passed and will become AMA policy. Other areas addressed include payment parity for telemedicine and MIPS reform.

Filed under:From the CollegeLegislation & Advocacy Tagged with:ACR advocacyAMA House of Delegates (HOD)House of Delegates interim meeting

Type I IFNs in Cutaneous Lupus & Dermatomyositis

Katie Robinson  |  October 14, 2024

Type I interferons (IFNs) play an important role in the immunopathogenesis of cutaneous lupus erythematosus and dermatomyositis skin inflammation, which could potentially be treated with IFN-targeted therapies.

Filed under:ConditionsMyositis Tagged with:Immunologytype I interferon

Zenobillis / shutterstock.com

In the Wake of Hurricanes Helene & Milton: Lessons Learned

Susan Bernstein  |  October 4, 2024

Editor’s note: As states prepare for Hurricane Milton, at least 223 people have died and hundreds are still unaccounted for in the destruction wrought by Hurricane Helene on Sept. 26. North and South Carolina, as well as Tennessee, were hard hit, and the U.S. medical system is being tested. Headlines include: “Helene Nearly Turned a…

Filed under:EMRsFacilityPractice Support Tagged with:Disaster preparationNatural disaster

Spotlight on Pediatric Rheumatology in Singapore

Jason Liebowitz, MD, FACR  |  September 26, 2024

A pioneer of pediatric rheumatology in Singapore, Dr. Elizabeth Ang details her unique clinical experiences.

Filed under:ConditionsEULAR/OtherGuidanceMeeting ReportsPediatric Conditions Tagged with:ACR/APLAR ExchangeAPLAR 2024

ACR Comments on 2025 Physician Fee Schedule

From the College  |  September 6, 2024

The ACR’s response to the Centers for Medicare & Medicaid Services addresses the likely harm of the proposed conversion factor on the solvency and stability of rheumatology practices. The comments also include recommendations on complex drug administration coding, inflation-adjusted drug rebates and extending telehealth flexibilities.

Filed under:From the CollegeLegislation & Advocacy Tagged with:ACR advocacyMedicare Physician Fee Schedule (MPFS)

Summary of Notable Provisions in CY 2025 Medicare PFS Proposed Rule

From the College  |  July 19, 2024

The ACR will provide comments on several provisions related to Medicare physician payment and the Quality Payment Program.

Filed under:Legislation & AdvocacyPractice Support Tagged with:Medicare Physician Fee Schedule (MPFS)Medicare ReimbursementQuality Payment Program (QPP)

State Copay Accumulator Legislation: An Overview

Joseph Cantrell, JD  |  June 25, 2024

As uncertainty persists around federal policies regarding copay accumulator programs, a growing number of states are stepping in. A total of 21 states have banned the programs and others are increasing transparency requirements

Filed under:Uncategorized Tagged with:copay accumulatorsstate legislation

Ethics Forum: Regarding Chatbots in Rheumatology

Biana Modilevsky, DO, & Kabita Nanda, MD  |  June 10, 2024

Chatbots are not a new concept, but have recently gained popularity and traction. Launched in late 2022, ChatGPT (Chat Generative Pre-Trained Transformer) is a web-based platform designed to simulate interactive conversations and deliver real-time data. It has quickly become a tool that provides instantaneous information that can be more focused than a Google search.1 We,…

Filed under:EthicsInsuranceTechnology Tagged with:artificial intelligencechatbotsEthics ForumHIPAA

Pharmacy Benefit Managers Under Scrutiny

Elizabeth Hofheinz, MPH, MEd  |  June 10, 2024

“When pharmacy benefit managers [PBMs] came into being 30 years ago, they were seen as an important component of the prescription distribution system [because] they could guide benefits and money between the patient, pharmacy and the manufacturer,” says Angus Worthing, MD, president of the Alliance for Transparent & Affordable Prescriptions (ATAP). Health insurance companies hire…

Filed under:Drug UpdatesLegislation & Advocacy Tagged with:drug pricingdrug pricing transparencypharmacy benefit managers (PBMs)

  • « Previous Page
  • 1
  • …
  • 21
  • 22
  • 23
  • 24
  • 25
  • …
  • 117
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences